Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
4
Lantheus
LNTH
5
Hutchmed (China)
HCM
(Q1)Mar 28, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 27, 2024 | (Q2)Jun 28, 2024 | (Q1)Mar 29, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 29, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 211.73%83.61M | 777.14%61.92M | 674.39%48.53M | -21.04%8.72M | -34.09%-22.15M | 327.75%26.82M | 28.91%7.06M | -67.61%6.27M | 234.37%11.04M | -175.70%-16.52M |
Net income from continuing operations | 173.43%5.94M | -53.31%39.22M | -54.53%38.12M | 434.38%21.72M | -905.92%-12.53M | -258.83%-8.09M | 198.04%83.99M | 1,267.49%83.84M | -174.31%-6.5M | -89.52%1.56M |
Operating gains losses | 134.03%377K | -78.32%315K | -373.40%-6.2M | 324.04%4.04M | 1,296.32%3.58M | -185.89%-1.11M | 120.60%1.45M | 437.85%2.27M | -50.79%-1.81M | 94.08%-299K |
Depreciation and amortization | -11.83%2.72M | -0.95%12.14M | -3.54%2.97M | -7.41%2.86M | 5.46%3.23M | 1.82%3.09M | -0.04%12.26M | 1.38%3.08M | -0.26%3.09M | 1.39%3.06M |
Deferred tax | 118.71%712K | 82.30%-16.44M | 85.49%-13.76M | 782.84%6.22M | -757.75%-5.09M | -795.80%-3.81M | -1,997.34%-92.86M | -3,164.66%-94.88M | 77.58%705K | 0.00%774K |
Other non cash items | -107.92%-19K | -70.36%569K | -41.99%134K | -79.60%81K | -80.65%114K | -65.86%240K | -43.83%1.92M | -89.01%231K | 3.93%397K | 5.18%589K |
Change In working capital | 120.75%63.62M | 27.49%-24.97M | 159.42%11.02M | -853.04%-36M | 2.76%-28.8M | 308.16%28.82M | 48.93%-34.43M | 876.09%4.25M | 117.71%4.78M | -4,069.84%-29.62M |
-Change in receivables | 126.25%79.61M | -16.96%-38.24M | 78.00%-6.63M | -768.57%-52.38M | 53.36%-14.42M | 71.39%35.19M | -54.35%-32.7M | -3,330.12%-30.14M | 1,174.62%7.83M | -535.95%-30.92M |
-Change in inventory | 149.05%2.24M | -76.35%8.37M | -91.46%1.78M | 37.75%10.52M | -96.32%642K | 56.66%-4.57M | 165.04%35.4M | 207.15%20.87M | 139.12%7.64M | 586.09%17.44M |
-Change in prepaid assets | ---8.36M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | -247.29%-8.82M | 89.42%-3.11M | 44.08%-4.89M | 5.50%10.47M | 18.60%-14.67M | 147.88%5.99M | -602.96%-29.36M | -293.12%-8.75M | -59.77%9.92M | -62.42%-18.02M |
-Change in other current assets | ---- | -87.45%3.2M | -65.38%6.69M | -20.27%3.27M | -137.18%-1.72M | -96.45%-5.04M | 403.30%25.48M | 881.16%19.32M | 145.58%4.1M | 79.16%4.63M |
-Change in other current liabilities | 46.15%-4.21M | 156.41%7.02M | 25.97%18.34M | 73.61%-3.77M | 111.73%263K | 25.38%-7.82M | -252.76%-12.44M | 63.32%14.56M | -182.48%-14.29M | -128.86%-2.24M |
-Change in other working capital | -37.86%3.15M | 89.39%-2.21M | 63.22%-4.27M | 60.53%-4.12M | 322.49%1.11M | 194.65%5.07M | -897.82%-20.82M | -425.81%-11.62M | 39.87%-10.43M | 75.29%-498K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 211.73%83.61M | 777.14%61.92M | 674.39%48.53M | -21.04%8.72M | -34.09%-22.15M | 327.75%26.82M | 28.91%7.06M | -67.61%6.27M | 234.37%11.04M | -175.70%-16.52M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 2.04%-1.87M | -8.39%-9.19M | -165.55%-2.35M | 63.70%-2.98M | -29.49%-1.95M | 18.02%-1.91M | -558.00%-8.48M | 292.32%3.58M | -336.13%-8.22M | -130.68%-1.5M |
Net PPE purchase and sale | 2.04%-1.87M | -8.39%-9.19M | 13.94%-2.35M | -55.74%-2.98M | -29.49%-1.95M | 18.02%-1.91M | 8.38%-8.48M | -46.48%-2.73M | -1.64%-1.92M | 51.01%-1.5M |
Net investment purchase and sale | ---- | --0 | --0 | ---- | ---- | ---- | --0 | --6.31M | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 2.04%-1.87M | -8.39%-9.19M | -165.55%-2.35M | 63.70%-2.98M | -29.49%-1.95M | 18.02%-1.91M | -558.00%-8.48M | 292.32%3.58M | -336.13%-8.22M | -130.68%-1.5M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -51.11%-36.07M | -566.71%-33.27M | 35.87%-1.29M | 19.17%2.94M | -444.07%-11.05M | -598.04%-23.87M | 88.43%-4.99M | 94.74%-2.01M | 215.38%2.47M | -127.44%-2.03M |
Net issuance payments of debt | ---500K | -94.56%-2M | -371.01%-650K | --480K | -147.84%-1.83M | --0 | 97.34%-1.03M | 99.64%-138K | --0 | 6.92%-740K |
Net common stock issuance | -82.12%-33.02M | -457.11%-23.42M | --0 | -11.01%3.09M | -837,100.00%-8.37M | -687.78%-18.13M | 234.76%6.56M | -99.38%6K | 2,966.12%3.47M | -100.34%-1K |
Net other financing activities | 55.56%-2.55M | 25.40%-7.85M | 66.03%-637K | 37.50%-625K | 34.57%-844K | 9.65%-5.74M | -66.93%-10.52M | -45.69%-1.88M | 48.21%-1M | -230.77%-1.29M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -51.11%-36.07M | -566.71%-33.27M | 35.87%-1.29M | 19.17%2.94M | -444.07%-11.05M | -598.04%-23.87M | 88.43%-4.99M | 94.74%-2.01M | 215.38%2.47M | -127.44%-2.03M |
Net cash flow | ||||||||||
Beginning cash position | 20.79%101.79M | -5.94%84.27M | -22.64%58.5M | -31.35%48.77M | -7.23%84.31M | -5.94%84.27M | -32.86%89.59M | -28.17%75.62M | -41.69%71.03M | -9.79%90.88M |
Current changes in cash | 4,307.24%45.66M | 403.81%19.46M | 472.75%44.9M | 64.00%8.68M | -75.26%-35.15M | 99.61%1.04M | 83.55%-6.41M | 137.97%7.84M | 143.22%5.29M | -177.65%-20.06M |
Effect of exchange rate changes | 259.00%1.59M | -278.33%-1.94M | -299.26%-1.61M | 251.29%1.06M | -287.08%-391K | -229.53%-1M | 122.22%1.09M | -83.68%808K | 83.71%-700K | 104.40%209K |
End cash Position | 76.78%149.04M | 20.79%101.79M | 20.79%101.79M | -22.64%58.5M | -31.35%48.77M | -7.23%84.31M | -5.94%84.27M | -5.94%84.27M | -28.17%75.62M | -41.69%71.03M |
Free cash flow | 228.13%81.73M | 3,823.94%52.73M | 1,204.29%46.19M | -37.16%5.74M | -33.71%-24.1M | 532.37%24.91M | 62.48%-1.42M | -79.75%3.54M | 190.34%9.13M | -196.08%-18.02M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |